DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2017-06-01

Last Posted Date: 2025-03-28

Lead Sponsor: Takeda

Target Recruit Count: 141

Registration Number: NCT03173092

Locations: 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸
Los Angeles Cancer Network/(Formerly -Pacific Cancer Medical Center), Anaheim, California, United States
🇺🇸
US Oncology Research, Colorado Springs, Colorado, United States

and more 18 locations

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-954
Drug: Itraconazole

First Posted Date: 2017-06-01

Last Posted Date: 2019-01-15

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT03173170

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States

ADYNOVATE Drug Use-Results Survey

Completed

Conditions: Hemophilia A

Interventions: Biological: ADYNOVATE

First Posted Date: 2017-05-30

Last Posted Date: 2025-02-04

Lead Sponsor: Takeda

Target Recruit Count: 135

Registration Number: NCT03169972

Locations: 🇯🇵
Matsuyama City, Japan, Matsuyama City, Ehime Prefecture, Japan
🇯🇵
Sapporo City, Sapporo City, Hokkaido, Japan
🇯🇵
Kyoto City, Kyoto City, Kyoto Prefecture, Japan

and more 46 locations

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Ixazomib

First Posted Date: 2017-05-30

Last Posted Date: 2023-12-07

Lead Sponsor: Takeda

Target Recruit Count: 774

Registration Number: NCT03169361

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Phase 1

Completed

Conditions: Developmental and/or Epileptic Encephalopathies

Interventions: Drug: TAK-935
Drug: Placebo

First Posted Date: 2017-05-25

Last Posted Date: 2021-01-07

Lead Sponsor: Takeda

Target Recruit Count: 18

Registration Number: NCT03166215

Locations: 🇺🇸
Xenoscience, Phoenix, Arizona, United States
🇺🇸
Medsol Clinical Research Center, Port Charlotte, Florida, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 8 locations

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 2

Completed

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Vedolizumab

First Posted Date: 2017-05-03

Last Posted Date: 2020-12-21

Lead Sponsor: Takeda

Target Recruit Count: 89

Registration Number: NCT03138655

Locations: 🇺🇸
Children's Center for Digestive Healthcare, Atlanta, Georgia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
University Hospitals Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States

and more 85 locations

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 30 mg dexlansoprazole capsules manufactured at TOB
Drug: 60 mg dexlansoprazole capsules manufactured at TOB
Drug: 30 mg dexlansoprazole capsules manufactured at TPC
Drug: 60 mg dexlansoprazole capsules manufactured at TPC

First Posted Date: 2017-04-27

Last Posted Date: 2019-06-14

Lead Sponsor: Takeda

Target Recruit Count: 116

Registration Number: NCT03131895

Locations: 🇺🇸
PRAHS Phase 1 unit, Salt Lake City, Utah, United States

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

Phase 4

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: Vonoprazan

First Posted Date: 2017-04-17

Last Posted Date: 2019-03-29

Lead Sponsor: Takeda

Target Recruit Count: 3

Registration Number: NCT03116841

Locations: 🇯🇵
Tokatsu Tsujinaka Hospital, Abiko, Chiba, Japan
🇯🇵
Aoyama Clinic, Kobe, Hyogo, Japan
🇯🇵
Saino Clinic, Tokorozawa, Saitama, Japan

and more 3 locations

IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

Phase 1

Terminated

Conditions: Poliomyelitis

Interventions: Biological: Reference IPV
Biological: sIPV Placebo
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

First Posted Date: 2017-03-28

Last Posted Date: 2020-01-31

Lead Sponsor: Takeda

Target Recruit Count: 340

Registration Number: NCT03092791

Locations: 🇵🇦
CEVAXIN - David, Chiriqui, Panama
🇵🇦
CEVAXIN Plaza Carolina - Ciudad de Panama, Ciudad de Panama, Panama
🇵🇦
CEVAXIN - 24 de Diciembre, Panama, Panama

and more 1 locations

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

Completed

Conditions: Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases

Interventions: Drug: Anti-TNF Therapy

First Posted Date: 2017-03-24

Last Posted Date: 2018-06-26

Lead Sponsor: Takeda

Target Recruit Count: 1731

Registration Number: NCT03090139

Locations: 🇦🇷
Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina
🇦🇷
Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 73 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy